Angiotech Pharmaceuticals announces commercial launch of the Tan Endoglide(TM) Endothelium Insertion System in the United States
23 Oktober 2009 - 3:00PM
PR Newswire (US)
VANCOUVER, Oct. 23 /PRNewswire-FirstCall/ -- Angiotech
Pharmaceuticals, Inc. (NASDAQ: ANPI; TSX: ANP), today announced the
commercial launch of the Tan EndoGlide(TM) Endothelium Insertion
System in the United States. Angiotech holds exclusive U.S.
distribution rights to market and distribute the Tan EndoGlide
Endothelium Insertion System, which it obtained in a supply
agreement with privately held Network Medical Products, Ltd.
Angiotech will launch the product during the American Academy of
Ophthalmology meeting, to be held in San Francisco, CA on October
24-27, 2009. "As less invasive cornea transplant techniques
continue to evolve, new devices are needed to safely deliver donor
tissue. The Tan EndoGlide is one of the first new devices on the
market designed to help surgeons handle and insert endothelial cell
tissue with minimal cell loss," said Steve Bryant, Senior Vice
President, Sales and Marketing for Angiotech. "We are excited to
announce that the Tan EndoGlide Endothelium Insertion System is now
available throughout the U.S. through our Ophthalmic Distributor
Specialties Sales Team." The Tan EndoGlide is a device used to
facilitate insertion of a donor endothelium during Endothelial
Keratoplasty. The device is used by Ophthalmologists adapting to
newer techniques to replace diseased corneal endothelium. The Tan
EndoGlide is specifically designed for use in Descemet's Stripping
Endothelial Keratoplasty (DSEK) and Descemet's Stripping Automated
Endothelial Keratoplasty (DSAEK) surgical procedures. About the Tan
EndoGlide Endothelium Insertion System The Tan EndoGlide, developed
by Network Medical Products, Ltd., is a medical device specifically
designed to offer surgeons support in reducing iatrogenic damage of
donor endothelium caused by manipulation and insertion of the donor
through a small incision. The device allows the surgeon to maintain
full control of the donor lenticule at all stages of insertion. The
patent pending cartridge design produces a "double-coil" loading of
the donor tissue for minimal endothelial touch. About Endothelial
Keratoplasty (EK) Endothelial Keratoplasty (EK) procedures allow
surgeons to preserve the majority of a recipient's cornea while
replacing the non-functioning or diseased inner portion of the
cornea with a healthy donor tissue. EK procedures require small
incisions and are more minimally invasive than Penetrating
Keratoplasty (PK) procedures. The primary advantages of EK
procedures over PK procedures are minimal astigmatism associated
with the surgery, and more rapid visual recovery. Forward Looking
Statements -------------------------- Statements contained in this
press release that are not based on historical fact, including
without limitation statements containing the words "believes,"
"may," "plans," "will," "estimates," "continues," "anticipates,"
"intends," "expects" and similar expressions, constitute
"forward-looking statements" within the meaning of the Private
Securities Litigation Reform Act of 1995 and constitute
"forward-looking information" within the meaning of applicable
Canadian securities laws. All such statements are made pursuant to
the "safe harbor" provisions of applicable securities legislation.
Forward-looking statements may involve, but are not limited to,
comments with respect to our objectives and priorities for the
remainder of 2009 and beyond, our strategies or future actions, our
targets, expectations for our financial condition and the results
of, or outlook for, our operations, research and development and
product and drug development. Such forward-looking statements
involve known and unknown risks, uncertainties and other factors
that may cause the actual results, events or developments to be
materially different from any future results, events or
developments expressed or implied by such forward-looking
statements. Many such known risks, uncertainties and other factors
are taken into account as part of our assumptions underlying these
forward-looking statements and include, among others, the
following: general economic and business conditions in the United
States, Canada and the other regions in which we operate; market
demand; technological changes that could impact our existing
products or our ability to develop and commercialize future
products; competition; existing governmental regulations and
changes in, or the failure to comply with, governmental
regulations; availability of financial reimbursement coverage from
governmental and third-party payers for products and related
treatments; adverse results or unexpected delays in pre-clinical
and clinical product development processes; adverse findings
related to the safety and/or efficacy of our products or products
sold by our partners; decisions, and the timing of decisions, made
by health regulatory agencies regarding approval of our technology
and products; the requirement for substantial funding to conduct
research and development, to expand manufacturing and
commercialization activities; and any other factors that may affect
our performance. In addition, our business is subject to certain
operating risks that may cause any results expressed or implied by
the forward-looking statements in this press release to differ
materially from our actual results. These operating risks include:
our ability to attract and retain qualified personnel; our ability
to successfully complete pre-clinical and clinical development of
our products; changes in our business strategy or development
plans; our failure to obtain patent protection for discoveries;
loss of patent protection resulting from third-party challenges to
our patents; commercialization limitations imposed by patents owned
or controlled by third parties; our ability to obtain rights to
technology from licensors; liability for patent claims and other
claims asserted against us; our ability to obtain and enforce
timely patent and other intellectual property protection for our
technology and products; the ability to enter into, and to
maintain, corporate alliances relating to the development and
commercialization of our technology and products; market acceptance
of our technology and products; our ability to successfully
manufacture, market and sell our products; the availability of
capital to finance our activities; our ability to restructure and
to service our debt obligations; and any other factors referenced
in our other filings with the applicable Canadian securities
regulatory authorities or the Securities and Exchange Commission
("SEC"). For a more thorough discussion of the risks associated
with our business, see the "Risk Factors" section in our annual
report for the year ended December 31, 2008 filed with the SEC on
Form 10-K, and our quarterly report for the three months ended June
30, 2009 filed with the SEC on Form 10-Q. Given these
uncertainties, assumptions and risk factors, investors are
cautioned not to place undue reliance on such forward-looking
statements. Except as required by law, we disclaim any obligation
to update any such factors or to publicly announce the result of
any revisions to any of the forward-looking statements contained in
this press release to reflect future results, events or
developments. (C)2009 Angiotech Pharmaceuticals, Inc. All Rights
Reserved. About Angiotech Pharmaceuticals Angiotech
Pharmaceuticals, Inc. is a global specialty pharmaceutical and
medical device company with over 1,500 dedicated employees.
Angiotech discovers, develops and markets innovative treatment
solutions for diseases or complications associated with medical
device implants, surgical interventions and acute injury. To find
out more about Angiotech (NASDAQ:ANPINASDAQ:TSX:NASDAQ:ANP), please
visit our website at http://www.angiotech.com/. EndoGlide is a
trademark of Coronet Medical Technologies Limited and is used by
Angiotech under license. DATASOURCE: Angiotech Pharmaceuticals,
Inc. CONTACT: Sharrifah Al-Salem, Investor Relations and Corporate
Communications, Angiotech Pharmaceuticals, Inc., (415) 293-4414,
Copyright
Angiotech Pharmaceuticals - Common Shares (MM) (NASDAQ:ANPI)
Historical Stock Chart
Von Aug 2024 bis Sep 2024
Angiotech Pharmaceuticals - Common Shares (MM) (NASDAQ:ANPI)
Historical Stock Chart
Von Sep 2023 bis Sep 2024